Effect of anti-VEGF treatment on nonperfusion areas in ischemic retinopathy
Author:
Corresponding Author:

Jing Luo. Department of Ophthalmology, the Second Xiangya Hospital, Central South University, 139 Middle Renmin Rd, Changsha 410011, Hunan Province, China. luojing001@csu.edu.cn

Affiliation:

Clc Number:

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    In recent years, retinal ischemia such as that which occurs in diabetic retinopathy (DR) and retinal vein occlusion (RVO) has become a hotspot of ischemic retinopathy research. High levels of vascular endothelial growth factor (VEGF) are recognized as a major cause of macular edema (ME) in DR and RVO. High concentrations of VEGF in the vitreous can lead to serious retinal ischemia and hypoxia and form retinal nonperfusion areas (NPAs). Different levels of retinal ischemia can represent disease severity and progression. Anti-VEGF therapy as the first-line treatment for ME has been found to be effective in improving vision, but there are still disputes about whether anti-VEGF therapy could improve retinal ischemia and achieve reperfusion of previously developed retinal NPAs. Here, we review and summarize studies of the effects of anti-VEGF drugs on retinal ischemia, especially NPAs.

    Reference
    Related
    Cited by
Get Citation

Zi-Yi Zhu, Yong-An Meng, Bin Yan, et al. Effect of anti-VEGF treatment on nonperfusion areas in ischemic retinopathy. Int J Ophthalmol, 2021,14(11):1647-1652

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
Publication History
  • Received:April 14,2021
  • Revised:July 29,2021
  • Adopted:
  • Online: October 27,2021
  • Published: